• +1-646-491-9876
    • +91-20-67278686

    Search

    Chemotherapy Induced Nausea and Vomiting - Pipeline Review, H1 2017

    Chemotherapy Induced Nausea and Vomiting - Pipeline Review, H1 2017

    • Report Code ID: RW0001689445
    • Category Healthcare
    • No. of Pages 88
    • Publication Month Mar-17
    • Publisher Name Global Markets Direct
    Report Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Chemotherapy Induced Nausea and Vomiting - Pipeline Review, H1 2017, provides an overview of the Chemotherapy Induced Nausea and Vomiting (Oncology) pipeline landscape.

    Chemotherapy induced nausea and vomiting or CINV is nausea and vomiting that results specifically from treatment with chemotherapy drugs. Symptoms include a rapid heart rate, sweating, dizziness and increased saliva. Risk factors include age, drug, dose, schedule of administration and route.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Chemotherapy Induced Nausea and Vomiting - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Chemotherapy Induced Nausea and Vomiting (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Chemotherapy Induced Nausea and Vomiting (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Chemotherapy Induced Nausea and Vomiting and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 3, 4, 2, 1, 9, 2 and 1 respectively.

    Chemotherapy Induced Nausea and Vomiting (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Report Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Chemotherapy Induced Nausea and Vomiting (Oncology).
    - The pipeline guide reviews pipeline therapeutics for Chemotherapy Induced Nausea and Vomiting (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Chemotherapy Induced Nausea and Vomiting (Oncology) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Chemotherapy Induced Nausea and Vomiting (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Chemotherapy Induced Nausea and Vomiting (Oncology)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Chemotherapy Induced Nausea and Vomiting (Oncology).
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Chemotherapy Induced Nausea and Vomiting (Oncology) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Chemotherapy Induced Nausea and Vomiting - Overview
    Chemotherapy Induced Nausea and Vomiting - Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Products under Development by Companies
    Chemotherapy Induced Nausea and Vomiting - Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Chemotherapy Induced Nausea and Vomiting - Companies Involved in Therapeutics Development
    Acacia Pharma Ltd
    Aphios Corp
    Astellas Pharma Inc
    Camurus AB
    Daewoong Pharmaceutical Co Ltd
    Heron Therapeutics Inc
    INSYS Therapeutics Inc
    Kyowa Hakko Kirin Co Ltd
    MannKind Corp
    Medlab Clinical Ltd
    Nemus Bioscience Inc
    RedHill Biopharma Ltd
    Serina Therapeutics Inc
    SoluBest Ltd
    Suda Ltd
    Tesaro Inc
    Therapix Biosciences Ltd
    Chemotherapy Induced Nausea and Vomiting - Drug Profiles
    (netupitant + palonosetron hydrochloride) - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    (palonosetron hydrochloride + Pro-netupitant) - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    APD-403 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    aprepitant - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    aprepitant - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    aprepitant - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Cannabis CINV - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    dronabinol - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    FK-886 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    fosnetupitant - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    granisetron hydrochloride - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    granisetron hydrochloride - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    granisetron hydrochloride ER - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    LPI-1504 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    LPI-1505 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    NB-1222 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    NB-2111 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ondansetron hydrochloride - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ondansetron hydrochloride - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ondansetron hydrochloride - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ondansetron hydrochloride CR - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    palmidrol - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    palonosetron hydrochloride - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    rolapitant hydrochloride - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SER-232 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Zindol - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Chemotherapy Induced Nausea and Vomiting - Dormant Projects
    Chemotherapy Induced Nausea and Vomiting - Discontinued Products
    Chemotherapy Induced Nausea and Vomiting - Product Development Milestones
    Featured News & Press Releases
    Feb 27, 2017: TESARO Receives Positive CHMP Opinion for VARUBY
    Feb 23, 2017: Tesaro Receives CHMP Positive Opinion for Varuby (rolapitant)
    Jan 12, 2017: Heron Announces Submission of CINVANTI NDA for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV)
    Jan 11, 2017: TESARO Receives Complete Response Letter for Rolapitant IV from U.S. FDA
    Oct 27, 2016: Mundipharma Launches Step-change Cancer Care Medicine Akynzeo in Singapore
    Sep 06, 2016: TESARO to present data on Rolapitant at the 2016 European Society for Medical Oncology Annual Meeting
    Jun 23, 2016: TESARO Announces Rolapitant Data Presentations at the 2016 MASCC/ISOO Annual Meeting on Supportive Care in Cancer
    Jun 04, 2016: TESARO Provides Update on Rolapitant IV at ASCO Investor Briefing
    May 18, 2016: TESARO Announces Two Abstracts on (VARUBI) Rolapitant to be Presented at the 2016 American Society of Clinical Oncology Annual Meeting
    Apr 12, 2016: Suda Granted Canadian Patent For Sud-002 Oral Spray To Treat Nausea & Vomiting
    Mar 23, 2016: TESARO Announces Validation of Marketing Authorisation Application for Oral Rolapitant by the European Medicines Agency
    Mar 14, 2016: TESARO Submits New Drug Application for Intravenous Rolapitant to the U.S. Food and Drug Administration
    Feb 01, 2016: Biologics Announces New Oncology Partnership
    Dec 15, 2015: Swissmedic Approves Akynzeo (netupitant/palonosetron) for use in the Prevention of Chemotherapy Induced Nausea and Vomiting in Switzerland
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Chemotherapy Induced Nausea and Vomiting, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017 (Contd..1), H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Chemotherapy Induced Nausea and Vomiting - Pipeline by Acacia Pharma Ltd, H1 2017
    Chemotherapy Induced Nausea and Vomiting - Pipeline by Aphios Corp, H1 2017
    Chemotherapy Induced Nausea and Vomiting - Pipeline by Astellas Pharma Inc, H1 2017
    Chemotherapy Induced Nausea and Vomiting - Pipeline by Camurus AB, H1 2017
    Chemotherapy Induced Nausea and Vomiting - Pipeline by Daewoong Pharmaceutical Co Ltd, H1 2017
    Chemotherapy Induced Nausea and Vomiting - Pipeline by Heron Therapeutics Inc, H1 2017
    Chemotherapy Induced Nausea and Vomiting - Pipeline by INSYS Therapeutics Inc, H1 2017
    Chemotherapy Induced Nausea and Vomiting - Pipeline by Kyowa Hakko Kirin Co Ltd, H1 2017
    Chemotherapy Induced Nausea and Vomiting - Pipeline by MannKind Corp, H1 2017
    Chemotherapy Induced Nausea and Vomiting - Pipeline by Medlab Clinical Ltd, H1 2017
    Chemotherapy Induced Nausea and Vomiting - Pipeline by Nemus Bioscience Inc, H1 2017
    Chemotherapy Induced Nausea and Vomiting - Pipeline by RedHill Biopharma Ltd, H1 2017
    Chemotherapy Induced Nausea and Vomiting - Pipeline by Serina Therapeutics Inc, H1 2017
    Chemotherapy Induced Nausea and Vomiting - Pipeline by SoluBest Ltd, H1 2017
    Chemotherapy Induced Nausea and Vomiting - Pipeline by Suda Ltd, H1 2017
    Chemotherapy Induced Nausea and Vomiting - Pipeline by Tesaro Inc, H1 2017
    Chemotherapy Induced Nausea and Vomiting - Pipeline by Therapix Biosciences Ltd, H1 2017
    Chemotherapy Induced Nausea and Vomiting - Dormant Projects, H1 2017
    Chemotherapy Induced Nausea and Vomiting - Dormant Projects, H1 2017 (Contd..1), H1 2017
    Chemotherapy Induced Nausea and Vomiting - Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development for Chemotherapy Induced Nausea and Vomiting, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products by Targets, H1 2017
    Number of Products by Stage and Targets, H1 2017
    Number of Products by Mechanism of Actions, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Top 10 Routes of Administration, H1 2017
    Number of Products by Stage and Top 10 Routes of Administration, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    Acacia Pharma Ltd
    Aphios Corp
    Astellas Pharma Inc
    Camurus AB
    Daewoong Pharmaceutical Co Ltd
    Heron Therapeutics Inc
    INSYS Therapeutics Inc
    Kyowa Hakko Kirin Co Ltd
    MannKind Corp
    Medlab Clinical Ltd
    Nemus Bioscience Inc
    RedHill Biopharma Ltd
    Serina Therapeutics Inc
    SoluBest Ltd
    Suda Ltd
    Tesaro Inc
    Therapix Biosciences Ltd

    Request for Sample

    Report Url http://www.reportsweb.com//chemotherapy-induced-nausea-and-vomiting-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//chemotherapy-induced-nausea-and-vomiting-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//chemotherapy-induced-nausea-and-vomiting-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments